These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 31289361)

  • 1. Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance.
    Totsch SK; Schlappi C; Kang KD; Ishizuka AS; Lynn GM; Fox B; Beierle EA; Whitley RJ; Markert JM; Gillespie GY; Bernstock JD; Friedman GK
    Oncogene; 2019 Aug; 38(34):6159-6171. PubMed ID: 31289361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.
    Bernstock JD; Hoffman SE; Chen JA; Gupta S; Kappel AD; Smith TR; Chiocca EA
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34204248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
    Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
    Front Immunol; 2021; 12():721830. PubMed ID: 34675919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of non-replicative and oncolytic replication-selective HSV vectors.
    Epstein AL; Rabkin SD
    Trends Mol Med; 2024 Aug; 30(8):781-794. PubMed ID: 38886138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
    Uche IK; Kousoulas KG; Rider PJF
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Armed" oncolytic herpes simplex viruses for brain tumor therapy.
    Todo T
    Cell Adh Migr; 2008; 2(3):208-13. PubMed ID: 19262110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The viral approach to breast cancer immunotherapy.
    Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
    J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic HSV: Underpinnings of Tumor Susceptibility.
    Kangas C; Krawczyk E; He B
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.
    Fukuhara H; Takeshima Y; Todo T
    Cancer Sci; 2021 Aug; 112(8):3293-3301. PubMed ID: 34036669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
    Waters AM; Johnston JM; Reddy AT; Fiveash J; Madan-Swain A; Kachurak K; Bag AK; Gillespie GY; Markert JM; Friedman GK
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):7-16. PubMed ID: 28319448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
    Hao M; Huang C; Xia N
    Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors.
    Sostoa J; Dutoit V; Migliorini D
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic HSV-1 for the treatment of brain tumours.
    Markert JM; Parker JN; Buchsbaum DJ; Grizzle WE; Gillespie GY; Whitley RJ
    Herpes; 2006 Nov; 13(3):66-71. PubMed ID: 17147910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.